



High-Cost Outlier Specialty Drug

Effective December 15, 2025, Medical Mutual requires that a unique reimbursement rate be agreed upon for certain high-cost specialty drugs. The provider can contact the network management contracting team to agree upon a reimbursement rate, which will be in line with one hundred percent (100%) of CMS or the wholesale acquisition cost (WAC) if there is no Medicare assigned rate. Unless there is an agreed upon reimbursement rate prior to claims submission, payment for these specialty drugs will be processed at one hundred percent (100%) of CMS or the wholesale acquisition cost (WAC) if there is no Medicare assigned rate.

Effective January 1, 2026, cellular and gene therapy products are included in the Optum Transplant Services and not subject to the High-cost Outlier Specialty Drug process. A complete list of cellular and gene therapy products approved by the U.S. Food & Drug Administration is available at <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products>.

The drugs listed below require a that a unique reimbursement rate be agreed upon for reimbursement:

HCPCS Code	Brand Name	Generic Name
A9513	Lutathera	lutetium Lu 177 dotatate
J0222	Onpattro	patisiran
J0223	Givlaari	givosiran
J0225	Amvuttra	vutrisiran
J0638	Ilaris	canakinumab
J0896	Reblozyl	luspatercept-aamt
J1299	Soliris	eculizumab
Q5151	Epysqli	eculizumab-aagh – <i>Drug added 4/23/26</i>
Q5152	Bkemv	eculizumab-aeeb – <i>Drug added 4/23/26</i>
J1303	Ultomiris	ravulizumab-cwvz
J1554	Asceniv	Immune Globulin (Human)
J1823	Uplinza	inebilizumab-cdon
J2326	Spinraza	nusinersen
J3241	Tepezza	teprotumumab-trbw
J7214	Altuviio	antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl
J9021	Rylaze	asparaginase erwinia chrysanthemi (recombinant)- rywn
J9028	Anktiva	nogapendekin alfa inbakicept-pmln
J9030	Blinctyo	blinatumomab
J9042	Adcetris	brentuximab vedotin
J9061	Rybrevant	amivantamab-vmjw
J9063	Elahere	mirvetuximab soravtansine-gynx
J9118	Asparlas	calaspargase pegol
J9138	Inlexzo	gemcitabine (intravesical) – <i>Drug added 4/29/26</i>

J9204	Poteligeo	mogamulizumab-kpkc
J9207	Ixempria	ixabepilone
J9210	Gamifant	emapalumab-lzsg
J9226	Supprelin LA	Histrelin implant
J9248	Hepzato	melphalan
J9266	Oncaspar	pegaspargase
J9272	Jemperli	dostarlimab-gxly
J9273	Tivdak	tisotumab vedotin-tftv
J9274	Kimmtrak	tebentafusp-tebn
J9298	Opdualag	nivolumab and relatlimab-rmbw
J9309	Polivy	polatuzumab vedotin-piiq
J9332	Vyvgart	efgartigimod alfa-fcab
J9334	Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc
J9347	Imjudo	tremelimumab-actl
J1411	Hemgenix	etranacogene dezaparvovec
J1412	Roctavian	valoctocogene roxaparvovec
J1413	Elevidys	delandistrogene moxeparvovec-rokl
J1414	Beqvez	fidanacogene elaparvovec-dzkt
J3391	Lenmeldy	atidarsagene autotemcel
J3392	Casgevvy	exagamglogene autotemcel
J3393	Zynteglo	betibeglogene autotemcel
J3394	Lyfgenia	lovotibeglogene autotemcel
J3398	Luxturna	voretigene neparvovec
J3399	Zolgensma	onasemnogene abeparvovec
J3401	Vyjuvek	beremagene geperpavec
J3402	Ryoncil	remestemcel-L-rknd
J3403	Encelto	revakinagene taroretcel-lwey
J3590/C9399	Kebilidi	eladocagene exuparvovec-tneq
J3590/C9399	Lantidra	donislecel
J3590/C9399	Omisirge	Omidubicel
J3404	Papzimeos	zopapogene imadenovec-drba
J3590/C9399	Rethymic	allogeneic processed thymus tissue-agdc
J3387	Skysona	elivaldogene autotemcel
J3389	Zevaskyn	prademagene zamikeracel
J3590/C9399	Kresladi	marnetegragegene autotemcel
J3590/C9399	Yartemlea	narsoplimab-wuug
J9029	Adstiladrin	nadofaragene firadenovec-vncg
J9325	Imlygic	talimogene laherparepvec
J9999/C9399	Amtagvi	Lifileucel
Q2041	Yescarta	axicabtagene ciloleucel
Q2042	Kymriah	tisagenlecleucel-T
Q2043	Provenge	sipuleucel-T

Q2053	Tecartus	brexucabtagene autoleucel
Q2054	Breyanzi	lisocabtagene maraleucel
Q2055	Abecma	idecabtagene vicleucel
Q2056	Carvykti	ciltacabtagene autoleucel
Q2057	Tecelra	afamitresgene autoleucel
Q2058	Aucatzyl	obecabtagene autoleucel